Noliterax (Indapamide, Perindopril Arginine)

Noliterax is an antihypertensive medication that acts on blood pressure regulation pathways.

• Hypertension: lowers systolic and diastolic blood pressure in patients with elevated readings.
• Essential hypertension: provides sustained control of primary high blood pressure.
• High blood pressure: contributes to reduced cardiovascular risk by maintaining target pressures.

• Indapamide blocks sodium reabsorption in the distal renal tubule, increasing urinary sodium and water excretion, while Perindopril arginine inhibits angiotensin‑converting enzyme, decreasing angiotensin II formation and reducing systemic vascular resistance. The combined actions produce additive blood‑pressure‑lowering effects.

Noliterax may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Dizziness: feeling light‑headed, especially after standing.
• Headache: mild to moderate intensity.
• Cough: dry, persistent throat irritation.
• Fatigue: general tiredness or lack of energy.
• Increased urination: more frequent need to void.
• Electrolyte imbalance: changes in potassium or sodium levels.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat.
• Severe hypotension: markedly low blood pressure causing faintness.
• Renal impairment: worsening kidney function.
• Hyperkalemia: elevated potassium concentration in blood.
• Neutropenia: reduced white blood cell count.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating Noliterax, clinicians should consider several safety factors.

• Blood pressure monitoring: check regularly to avoid excessive lowering.
• Renal function assessment: evaluate serum creatinine and eGFR.
• Electrolyte surveillance: monitor potassium and sodium levels.
• Caution in diabetes: watch for changes in glucose control.
• Avoid in severe hepatic impairment: limited data support use.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Noliterax can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of hyperkalemia.
• Aliskiren in diabetic patients: additive renin‑angiotensin blockade.
• Lithium: increased lithium levels and toxicity.
• NSAIDs: may blunt antihypertensive effect and impair renal function.
• ACE inhibitor with other ACE inhibitors or ARBs: heightened risk of renal dysfunction.

Moderate Interactions (Monitor Closely)

• Thiazide‑type diuretics: additive electrolyte disturbances.
• Other antihypertensives: may cause excessive blood pressure drop.
• Diuretics causing dehydration: monitor volume status.
• Antidiabetic agents: potential enhancement of hypoglycaemia.
• Antimicrobials (e.g., trimethoprim): may increase potassium levels.